Diindolylmethane.

Indole-3-carbinol is the compound DIM is made from: stomach acid condenses two I3C molecules into the dimer. Supplementing DIM directly skips that acid-dependent step, which varies with gastric pH and with acid-lowering medication. Taking both delivers the same end compound by two routes rather than adding a second action.

Sulforaphane comes from glucoraphanin and activates the Nrf2 pathway; DIM comes from glucobrassicin and acts largely through the aryl hydrocarbon receptor. Both induce phase II conjugating enzymes, arriving at the same output by different receptors. Cruciferous formulas carry both for that reason.

Broccoli sprout extract supplies glucoraphanin, and its conversion to sulforaphane needs myrosinase from the plant or from gut bacteria. DIM needs no such enzymatic step once it is supplied as the dimer. The two cover complementary parts of the cruciferous chemistry.

Calcium D-glucarate releases glucaro-1,4-lactone, which inhibits bacterial beta-glucuronidase in the gut and so limits the deconjugation that sends glucuronidated compounds back into circulation. DIM works upstream, on the hydroxylation and conjugation steps. Together they cover formation and clearance of the same conjugates.

Catechol-O-methyltransferase needs magnesium in its active site to transfer a methyl group onto catechol oestrogens. DIM shifts hydroxylation toward the catechol pathway, which increases the substrate that enzyme has to handle. The cofactor relationship is textbook.

SAM-e is the universal methyl donor that COMT uses to methylate catechol metabolites. Every methylation consumes one SAM-e molecule and produces S-adenosylhomocysteine. Where DIM increases catechol formation, methyl group supply becomes the step to keep stocked.

5-methyltetrahydrofolate donates its methyl group to homocysteine, regenerating methionine and from there SAM-e. That cycle is what keeps methyl donors available for COMT. The link between folate status and methylation capacity is settled biochemistry.

Methionine synthase is a B12-dependent enzyme, and without it the methyl group on folate cannot reach homocysteine. The result is folate trapped in a form that cannot regenerate SAM-e. Any formula built around methylation capacity has to carry both.

Betaine remethylates homocysteine through betaine-homocysteine methyltransferase, a folate-independent route to methionine and then SAM-e. It runs mainly in liver and kidney. It is the backup path for the same methyl supply COMT draws on.

Pyridoxal-5-phosphate is the cofactor for cystathionine beta-synthase, which sends homocysteine down the transsulfuration route toward cysteine. That is how the methylation cycle disposes of its by-product rather than accumulating it. The cofactor role is established.

Glutathione is the direct conjugation substrate for the transferases DIM induces. Oral glutathione is absorbed less predictably than its cysteine precursor, which is why formulas often use both. The pathway relationship itself is settled.

Methionine is adenosylated to form SAM-e, the methyl donor spent on every COMT reaction. Dietary and supplemental methionine feed that pool directly. The step is textbook biochemistry.

Caffeine is cleared predominantly by CYP1A2, the enzyme DIM induces through the aryl hydrocarbon receptor. Induction shortens caffeine's half-life, so the same coffee feels weaker or wears off sooner. This is a well-described direction of interaction for cruciferous compounds generally.

Quercetin inhibits CYP1A2 and also competes for the sulfotransferases and UGTs that handle DIM and its products. DIM pushes the same enzymes the other way by inducing them. The net direction in a person taking both has not been measured.

Piperine inhibits intestinal glucuronidation and CYP3A4, which raises systemic exposure to several co-ingested compounds. Adding it to an enzyme-inducing compound like DIM pushes clearance in two directions at once. Read the pairing as a formulation decision with an unmeasured net effect rather than a straightforward absorption gain.

DIM is highly lipophilic and dissolves poorly in water, so absorption-enhanced preparations disperse it in a lipid matrix that commonly includes vitamin E as both a carrier component and an antioxidant. The vitamin E here serves the delivery system. The chemistry of the dispersion is what changes exposure, not the vitamin itself.

Phospholipid dispersion systems are the standard way poorly water-soluble crystalline compounds like DIM are made to disperse in gut fluid. The phospholipid forms mixed micelles with bile salts. This is delivery chemistry, not a second active.

A lipophilic compound taken with dietary fat triggers bile release and micelle formation, the route by which fat-soluble material crosses the enterocyte membrane. Medium-chain triglycerides supply that lipid signal in a stable, low-oxidation carrier. Taking DIM with any meal fat works on the same principle.

Silymarin flavonolignans influence phase II conjugating enzymes and hepatocyte membrane behaviour. DIM induces phase I and phase II enzymes through a receptor route. They meet in the same hepatic clearance machinery and are often formulated together on that basis.

Conjugated steroid metabolites are excreted in bile, and fibre in the lumen reduces how much is deconjugated and reabsorbed. DIM changes which metabolites are formed upstream. The fibre acts on the exit route rather than on the chemistry.

Gut bacteria produce beta-glucuronidase, which cleaves glucuronide conjugates and returns the freed compound to circulation. The composition of that microbial community therefore affects how much of a conjugated metabolite is recycled. DIM alters the metabolites entering that loop, not the loop itself.

Flaxseed lignans are converted by gut bacteria to enterolignans, which interact weakly with oestrogen receptors. DIM acts on metabolism rather than on the receptor. Formulas combine them because the points of action differ, and the combination has not been trialled.

EGCG is a substrate for catechol-O-methyltransferase and competes for the same methyl-transfer capacity that catechol metabolites use. DIM increases the catechol load. Two substrates for one magnesium-dependent enzyme is a competition to note, and its size in people has not been measured.

Curcumin modulates several phase I and phase II enzymes and competes for intestinal glucuronidation capacity. DIM induces some of the same enzymes. The two together produce a mixed picture that no combination study has resolved.